What is the present valuation and projected CAGR of the benign prostatic hyperplasia (bph) treatment devices and equipment market?
The benign prostatic hyperplasia (BPH) treatment devices and equipment market size has grown strongly in recent years. It will grow from $1.29 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to aging population, awareness and diagnosis, healthcare access, personalized treatment.
The benign prostatic hyperplasia (BPH) treatment devices and equipment market size is expected to see strong growth in the next few years. It will grow to $1.8 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to minimally invasive techniques, emerging markets growth, regulatory support, value-based healthcare. Major trends in the forecast period include non-surgical and office-based procedures, laser and radiofrequency technologies, telemedicine and remote consultation, patient education and engagement.
Get Your Free Sample of The Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2431&type=smp
What key drivers have fueled the benign prostatic hyperplasia (bph) treatment devices and equipment market’s development over the years?
The increase in the number of prostate cancer cases is anticipated to drive the growth of the benign prostatic hyperplasia market going forward. Prostate cancer refers to a type of cancer that develops in the prostate gland, which is a small, walnut-sized gland located just below the bladder in men. the increase in prostate cancer cases often results in a higher number of older men seeking medical attention for prostate-related issues. This leads to the identification and management of benign prostatic hyperplasia. For instance, in February 2023, according to the American Society of Clinical Oncology (ASCO), a US-based professional organization that publishes patient information on the cancer.net website, there were an estimated 288,300 men in the United States with prostate cancer in 2023, and there were 268,490 new cases and 34,500 deaths from prostate cancer in 2022. Therefore, the increase in the number of prostate cancer cases is driving the growth of the benign prostatic hyperplasia market.
What is the segmentation for the benign prostatic hyperplasia (bph) treatment devices and equipment market?
The benign prostatic hyperplasia (BPH) treatment devices and equipment market covered in this report is segmented –
1) By Product: Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants
2) By Procedure Type: Transurethral Needle Ablation (TUNA), Transurethral Resection Of Prostate (TURP), Transurethral Incision Of Prostate (TUIP), Transurethral Microwave Thermotherapy (TUMT), Laser Surgery, Other Procedure Types
3) By End-User: Hospitals, Ambulatory Surgical Centres (ASC), Clinics, Home
Subsegments:
1) By Resectoscopes: Bipolar Resectoscopes, Monopolar Resectoscopes, High-Performance Resectoscopes
2) By Radiofrequency Ablation Device: Single-Needle Radiofrequency Ablation, Multi-Needle Radiofrequency Ablation
3) By Urology Lasers: Holmium Lasers, Diode Lasers, Green Light Lasers
4) By Prostatic Stents: Temporary Prostatic Stents, Permanent Prostatic Stents
5) By Implants: Prostatic Urethral Lift (PUL) Implants, Balloon-Expandable Stents, Permanent Implants for BPH Treatment
Order your report now for swift delivery
Who are the most influential companies in the benign prostatic hyperplasia (bph) treatment devices and equipment market?
Major companies operating in the benign prostatic hyperplasia (BPH) treatment devices and equipment market include Karl Storz, Lumenis Ltd., Olympus Corporation, Urologix LLC, Boston scientific Inc., Endo International plc, NeoTract Inc., OmniGuide Inc., Medifocus Inc., ProArc Medical Ltd., Teleflex Incorporated, Medtronic plc, Urotech Devices, Prostalund Operations AB, Baxter International, NxThera Inc., Richard Wolf GmbH, Coloplast A/S, Siemens Healthineers, Quest Pharmatech, Protox Therapeutics, IntelGenx Technologies Corp, Astellas Pharma Inc., Ipsen S.A., Biolitec AG, BVM Medical, Convergent Laser Technologies, Cook Medical, GreenLight Technologies, Merit Medical Systems, Pnn Medical A/S, PROCEPT BioRobotics, Prosenex, ProSolv CardioVascular Inc., Quanta System, Rocamed SAM, RZ Medizintechnik GmbH, SRS Medical Systems, UroShape LLC, Vertebron Inc.
What are the top industry trends projected to impact the benign prostatic hyperplasia (bph) treatment devices and equipment market?
Major companies operating in the benign prostatic hyperplasia market are focused on developing innovative products, such as the UroLift 2 System and the UroLift ATC advanced tissue control system, to provide reliable services to the market. The UroLift 2 System and the UroLift ATC advanced tissue control system are launched for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). For instance, in May 2022, Teleflex Incorporated, a US-based medical device company, launched the UroLift 2 System and UroLift ATC. The UroLift 2 System is a delivery system designed to access the prostatic urethra and deliver permanent UroLift implants through the lobes of the prostate, and the UroLift ATC advanced tissue control system is a minimally invasive procedure to treat symptoms of an enlarged prostate. This is an evolutionary approach to treating benign prostatic hyperplasia (BPH) that lifts and holds the enlarged prostate tissue as it no longer blocks the urethra.
What are the major regional insights for the benign prostatic hyperplasia (bph) treatment devices and equipment market, and which region holds the top position?
North America was the largest region in the benign prostatic hyperplasia (BPH) treatment devices and equipment market in 2023. Western Europe was the second-largest region in the global benign prostatic hyperplasia (BPH) treatment devices and equipment market. The regions covered in the benign prostatic hyperplasia (BNH) treatment devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Report 2025 Offer?
The benign prostatic hyperplasia (bph) treatment devices and equipment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Benign prostatic hyperplasia or benign prostatic hypertrophy is a condition of prostate gland enlargement which causes blockade of urethra, the tube that carries urine from the bladder.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2431
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
